首页> 美国卫生研究院文献>Netherlands Heart Journal >The rationale of using cerebral embolic protection devices during transcatheter aortic valve implantation
【2h】

The rationale of using cerebral embolic protection devices during transcatheter aortic valve implantation

机译:经导管主动脉瓣植入术中使用脑栓塞保护装置的基本原理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aortic valve stenosis is one of the most common valvular abnormalities, which can manifest as angina, syncope, dyspnoea and sudden cardiac death. Transcatheter aortic valve implantation (TAVI) has been introduced as an alternative to surgical valve replacement in patients with severe aortic valve stenosis, resulting in less morbidity, shorter time to recovery and similar mortality rates. Progress in this field has reduced complication rates. However, the incidence of peri-procedural stroke remains relatively high (around 4%). To fully utilise the potential of TAVI, cerebral embolic protection devices (CEPD) have been developed and introduced. In this position paper, we aim to summarise the available data on several CEPD.
机译:主动脉瓣狭窄是最常见的瓣膜异常之一,可表现为心绞痛,晕厥,呼吸困难和心源性猝死。经导管主动脉瓣植入术(TAVI)已作为严重主动脉瓣狭窄患者的外科瓣膜置换术的替代方案,从而降低了发病率,缩短了恢复时间并降低了死亡率。该领域的进展降低了并发症发生率。但是,围手术期卒中的发生率仍然相对较高(约4%)。为了充分利用TAVI的潜力,已经开发并引入了脑栓塞保护装置(CEPD)。在本立场文件中,我们旨在总结一些CEPD的可用数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号